Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | MAPK3 | P27361 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 8/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19409147 | 0.96 | FGFR4 (0.34) | TAS1R3TAS1R1FGFR4FGFR1MAPK3 | |
| SCHEMBL9151004 | 0.92 | TAS1R3 (0.42) | TAS1R3TAS1R1FGFR4FGFR1MAPK3 | |
| SCHEMBL8362132 | 0.92 | TAS1R3 (0.42) | TAS1R3TAS1R1FGFR4FGFR1MAPK3 | |
| SCHEMBL9147601 | 0.92 | TAS1R3 (0.42) | TAS1R3TAS1R1FGFR4FGFR1MAPK3 | |
| SCHEMBL20959559 | 0.82 | EPHX1 (0.42) | TAS1R3TAS1R1HTTNPC1SMN1; SMN2 | |
| SCHEMBL8388655 | 0.82 | EPHX1 (0.42) | TAS1R3TAS1R1HTTNPC1SMN1; SMN2 | |
| SCHEMBL17371292 | 0.82 | PSEN1 (0.41) | TAS1R3TAS1R1FGFR4FGFR1MAPK3 | |
| SCHEMBL18972296 | 0.80 | FGFR4 (0.39) | TAS1R3TAS1R1FGFR4FGFR1MAPK3 | |
| SCHEMBL25293196 | 0.78 | TAS1R3 (0.60) | TAS1R3TAS1R1SMN1; SMN2 | |
| SCHEMBL15938041 | 0.78 | MMP2 (0.53) | TAS1R3TAS1R1FGFR4FGFR1MAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230097422-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-30 | — | — | US | disclosed |
| US-11319329-B2 | Inhibitors of Bruton's tyrosine kinase and methods of their use | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-03 | — | — | US | disclosed |
| US-20210101910-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-08 | — | — | US | disclosed |
| US-10934310-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | JANSSEN PHARMACEUTICA NV (BE) | 2021-03-02 | — | — | US | disclosed |
| EP-3719022-A1 | POLYCYCLIC COMPOUNDS AS INHIBITORS OF BRUTON'S TYROSINE KINASE | Janssen Pharmaceutica NV (BE) | 2020-10-07 | — | — | EP | disclosed |
| US-10717745-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | JANSSEN PHARMACEUTICA NV (BE) | 2020-07-21 | — | — | US | disclosed |
| EP-3386991-B1 | POLYCYCLIC COMPOUNDS AS INHIBITORS OF BRUTON'S TYROSINE KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2020-06-03 | — | — | EP | disclosed |
| US-20190276471-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2019-09-12 | — | — | US | disclosed |
| US-20170283430-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934310-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | ABL1, BTK, LYN | TAS1R3 4638/4885TAS1R1 4609/4885FGFR4 2584/4885 |
| US-20170283430-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | ABL1, BTK, LYN | TAS1R3 4638/4885TAS1R1 4609/4885FGFR4 2584/4885 |
| US-20230097422-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | ABL1, BTK, LYN | TAS1R3 4638/4885TAS1R1 4609/4885FGFR4 2584/4885 |
| US-10717745-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | ABL1, BTK, LYN | TAS1R3 4638/4885TAS1R1 4609/4885FGFR4 2584/4885 |
| US-20210101910-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | ABL1, BTK, MYLK2 | TAS1R3 4636/4885TAS1R1 4580/4885FGFR4 2635/4885 |
| US-20190276471-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | ABL1, BTK, LYN | TAS1R3 4638/4885TAS1R1 4609/4885FGFR4 2584/4885 |
| US-11319329-B2 | Inhibitors of Bruton's tyrosine kinase and methods of their use | ABL1, BTK, MYLK2 | TAS1R3 4636/4885TAS1R1 4580/4885FGFR4 2635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.